| Literature DB >> 26472965 |
Eun-Kyoung Koh1, Ji-Eun Sung1, Ji-Eun Kim1, Jun Go1, Sung-Hwa Song1, Hyun-Ah Lee1, Hong-Joo Son2, Young-Jin Jung1, Yong Lim3, Dae-Youn Hwang1.
Abstract
Some polymers and bioactive compounds derived from Styela clava tunic (SCT) have been reported as traditional medicine for the treatment of inflammation, oxidative stress and surgical wounds although there is little scientific evidence of their liver and kidney toxicity. To investigate the toxicity of ethanol extracts of SCT (EtSCT) in the liver and kidney of ICR mice, alterations in related markers including body weight, organ weight, urine composition, liver pathology and kidney pathology were analyzed following oral administration of 50 and 100 mg/kg body weight/day of EtSCT for 14 days. EtSCT showed a high level of free radical scavenging activity for DPPH (93.1%) and NO (16.2%) as well as the presence of 14.8 mg/mL of flavonoids and 36.2 mg/mL of phenolics, while EtSCT treated groups did not show any significant alterations in the body and organ weight, clinical phenotypes, urine parameters or mice mortality when compared with the vehicle treated group. In addition, constant levels of serum biochemical markers including alanine phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and serum creatinine (CRE) were maintained. Moreover, no specific histopathological features induced by most toxic compounds were observed in liver and kidney sections stained with hematoxilin and eosin. Therefore, the present results indicate that EtSCT with strong antioxidant activity cannot induce any specific toxicity in liver and kidney organs of ICR at doses of 100 mg/kg body weight/day.Entities:
Keywords: Styela clava tunic; antioxidant activity; hepatotoxicity; histopathology; nephrotoxicity
Year: 2015 PMID: 26472965 PMCID: PMC4602079 DOI: 10.5625/lar.2015.31.3.125
Source DB: PubMed Journal: Lab Anim Res ISSN: 1738-6055
Figure 1Preparation procedures of SCT powder and alteration in body weight. (A) Preparation procedures and analysis of SCT powder. (a-c) Following collection from the beach, samples were treated with 10% H2O2 solution and then subjected to milling. (d) Particle size analyses, showing individual and cumulative distribution of particles at the same time. (B) The body weight of subset groups was measured using an electrical balance.
Components and properties of EtSCT
| Categories | Concentration (mg/mL) |
|---|---|
| Flavonoids | 14.8 |
| Phenolic contents | 36.2 |
*DPPH; 2,2-diphenyl-1-picrylhydrazyl, NO; Nitric oxide.
Alteration of organ weights of ICR mice
| Organs | Control | Vehicle | LEtSCT | HEtSCT |
|---|---|---|---|---|
| Brain (g) | 0.50±0.019 | 0.50±0.015 | 0.50±0.016 | 0.51±0.055 |
| Testis (g) | 0.28±0.027 | 0.26±0.009 | 0.26±0.042 | 0.26±0.027 |
| Liver (g) | 2.02±0.279 | 1.96±0.186 | 1.81±0.120 | 1.74±0.106a |
| Kidney (g) | 0.33±0.029 | 0.28±0.072 | 0.31±0.027 | 0.31±0.039 |
| Spleen (g) | 0.17±0.070 | 0.17±0.055 | 0.14±0.023 | 0.17±0.054 |
| Thymus (g) | 0.09±0.020 | 0.09±0.020 | 0.07±0.018 | 0.05±0.010a,b |
| Heart (g) | 0.20±0.009 | 0.19±0.016 | 0.18±0.014a | 0.18±0.016a |
| Lung (g) | 0.29±0.025 | 0.26±0.009a | 0.26±0.011a | 0.25±0.021a |
*The data is reported as the mean±SD from three replicates. a, P<0.05 is the significance level compared to the control group. b, P<0.05 is the significance level compared to the vehicle group. Control; no treated group, Vehicle; vehicle treated group, LEtSCT; low dose of EtSCT treated group, HEtSCT; high dose of EtSCT treated group.
Alteration of urine parameters of ICR mice
| Parameters | Control | Vehicle | LEtSCT | HEtSCT |
|---|---|---|---|---|
| Ketones (mg/dL) | 9.58±1.020 | 7.50±2.738 | 7.50±2.738 | 8.21±2.377 |
| Ascorbic acid (mg/dL) | 45.83±10.206 | 28.33±18.073 | 36.07±17.903 | 40.00±13.768 |
| Leucocytes (WBC/ìL) | 20.00±8.660 | 10.00±0.000 | 10.00±0.000 | 14.50±6.708 |
| pH | 7.00±0.447 | 6.75±0.418 | 7.07±0.449 | 6.82±0.372 |
| Specific gravity | 1.01±0.003 | 1.01±0.002 | 1.01±0.002 | 1.01±0.007 |
*The data is reported as the mean±SD from three replicates. Control; no treated group, Vehicle; vehicle treated group, LEtSCT; low dose of EtSCT treated group, HEtSCT; high dose of EtSCT treated group.
Alteration of serum parameters of ICR mice
| Parameters | Control | Vehicle | LEtSCT | HEtSCT |
|---|---|---|---|---|
| ALT(mg/dL) | 29.57±6.99 | 33.28±4.57 | 29.57±4.57 | 30.85±5.78 |
| AST (mg/dL) | 81.00±7.76 | 79.42±15.94 | 71.28±7.91 | 98.71±17.74 |
| ALP (mg/dL) | 69.00±24.89 | 81.14±11.58 | 77.71±11.70 | 71.28±19.49 |
| LDH (g/dL) | 1.23±0.39 | 0.87±0.31 | 0.81±0.17 | 0.81±0.34 |
| BUN (mg/dL) | 27.01±5.82 | 20.55±2.31 | 21.15±2.19 | 23.88±5.34 |
| CRE (mg/dL) | 0.41±0.06 | 0.37±0.11 | 0.41±0.06 | 0.34±0.07 |
| Total protein (g/dL) | 4.68±0.343 | 4.54±0.250 | 4.81±0.285 | 4.74±0.350 |
| Total bilirubin (U/L) | 0.12±0.075 | 0.18±0.037 | 0.20±0.000 | 0.15±0.054 |
*The data is reported as the mean±SD from three replicates. Control; no treated group, Vehicle; vehicle treated group, LEtSCT; low dose of EtSCT treated group, HEtSCT; high dose of EtSCT treated group.
Figure 2Effects of EtSCT treatment on histological features of the liver and kidney. (A) Liver tissues were stained with H&E and cellular morphology was viewed at 400× magnification. (B) Kidney tissues were stained with H&E, and cellular morphology was viewed at 400× magnification. Control; no treated group, Vehicle; vehicle treated group, LEtSCT; low dose of EtSCT treated group, HEtSCT; high dose of EtSCT treated group.